This website is for educational purposes only and does not constitute investment advice. Always do your own research and assess your own risk tolerance before making investment decisions.

US End-of-Day Verdict 18 Aug 2026, 16:00:00 GMT-4

Sector ETFs — End-of-Day Verdict

NO ACTION - 0 ACQUIRE, 0 DISPOSE, 0 ANTICIPATE - plus 1 MANDATED WITHDRAWAL (UFO). Six names cleared the conviction floor, the widest bullish board in five weeks, and not one cleared the economics bar the book itself used to admit UFO a session earlier. The three highest-conviction prints are all the SAME trade - the Moderna/Merck melanoma readout (healthcare +3.5%, best day since April 2025, record sector high) plus the Treasury's expanded 10-30y buyback (gold to a two-month high) - bought after it happened: XLV (adj 90) closed AT its 52-week high with RSI 75.4, 1.39 ATR past a buy-stop the market has already run through, and its own Est_12W sits 2.09% BELOW the close (SE-2 on both legs) = 0.15x at the real price; IBB (adj 82) closed AT its 52-week high with RSI 80.4 after +6.58%, risking 12.75% to make 1.69% = 0.13x; GLD (adj 83) has a NEGATIVE four-week estimate (vs a close). XLF (adj 66) is the honest near-miss - best economics on the board at 1.57x with a genuine 1.16-ATR stop and the L1-favoured PullbackBuy_VWAP family, three of four written re-arm legs now PASS, and it is declined on leg 3 alone (entry = the close exactly), with Est_12W below entry for a third session. XLP (adj 83, first STRONG BUY of the run, SE-2 clear for the first time) is declined a third time on a 0.64-ATR stop inside one ordinary session's range, on the family whose measured stop_first is 0.667. XLY has the best-BUILT order in the book (1.07-ATR stop, no chase) and is still declined on a negative Est_4W. SOXX prints the highest-conviction BEARISH read in the book (FailedBreakout_Down_20D, conv 71, -2.21%, Est_12W -5.78%) with SMH collapsing -> 42 in two sessions - the rotation read the gauge exists to produce, with NVIDIA six sessions out. HONEST ACCOUNTING: yesterday's slot-ineligible decline on IBB at COST 7.23%; the same count rule saved 7.06% on SOXX and 6.4% on SMH - net roughly flat with enormous variance, and it demonstrably cannot distinguish a noise flip from a catalyst ignition (systemic finding #2).

Recommendations

0 to acquire · 0 to dispose

TickerNameCloseActionAction Price Where to act — a buy-limit on a pullback or a buy-stop above resistance, not the current price. Sanity-check vs Close: on a held name, an action price stranded above the close means the queued level was set when the stock was higher — stale, awaiting reprice. Stop The risk-defined exit, set below the entry for a long (~1.2–1.8×ATR). A held long whose Stop sits at/above the Close is already below its stop — a stale box awaiting reprice. 1wk Model estimate of the likely price at this horizon — a forward projection, not a guarantee, and separate from the trade's Action Price or Stop. Where the ML estimator is enabled these are per-ticker calibrated forecasts (~80% coverage band) that are refreshed periodically and can drift between refreshes; otherwise they're interpolated from the signal's swing target. Confirm against the settled close. 4wk Model estimate of the likely price at this horizon — a forward projection, not a guarantee, and separate from the trade's Action Price or Stop. Where the ML estimator is enabled these are per-ticker calibrated forecasts (~80% coverage band) that are refreshed periodically and can drift between refreshes; otherwise they're interpolated from the signal's swing target. Confirm against the settled close. 12wk Model estimate of the likely price at this horizon — a forward projection, not a guarantee, and separate from the trade's Action Price or Stop. Where the ML estimator is enabled these are per-ticker calibrated forecasts (~80% coverage band) that are refreshed periodically and can drift between refreshes; otherwise they're interpolated from the signal's swing target. Confirm against the settled close. Rationale
XBISPDR S&P Biotech ETF169.55WATCH169.55160.10168.99 (-0.3%)171.52 (+1.2%)175.50 (+3.5%)Biotech jumped 5.9% to a fresh 52-week high on the Moderna/Merck trial win; if this position is held it is a clear hold, not a trim - the gain is not yet large enough to trigger our profit-taking rule, no deterioration warning has printed, and the one-year outlook is still above today's price. We are raising the protective stop to lock in more of the move. Detail: BRANCH-CONDITIONAL - portfolio JSON shows (ground truth = FLAT, 08-07 card effectively SKIPPED); on the instructed branch @. On that branch: + / +8.70% = in one session; gain 2.87 ATR, just UNDER the 3.00-ATR arm threshold, Exit_Warning blank, so ADR-0012 cannot arm and no tick can fire. Est_12W = +3.51% above the close, so L2 does not fire. Close is / 8.6% clear of the stop. The AVOID/ReversalDown_Overbought print resolves to [HOLD] in Signal_Rationale and its Action_Rationale reads 'Flat; do not open (long-only)' - a don't-buy-here print, not a sell; pillars remain constructive (Trend 89, EMA20>EMA50>EMA200). TRAIL-RAISE -> (close - 2.0x ATR), closing basis, never widened; the model's Stop_Price is a short-side level and is discarded. FOUR ADR-0019 cards still need a human: trade buy/skip for 07-30 IBB, 08-06 IBB, 08-07 XBI, and trade skip AIQ 08-07. · news

Outcome & track record

Accuracy at the time of this record.

30 Graded decisions Past recommendations old enough to score against what actually happened (target hit / stopped out / closed). This is the evidence base — the bigger the number, the more history behind the calls. Click to inspect every one. See the decisions →
-0.068 1-week calibration How much of the eventual 4-week move typically shows up in the first week (0 = almost none, 1 = most of it). Use it to read the 1-week estimates: a low number means prices drift toward the target slowly, so don't over-read a soft week-1.
50 Published records How many dated end-of-day verdicts exist for this book — the length of the public track record you can browse in the Archive below.

This website is for educational purposes only and does not constitute investment advice. Always do your own research and assess your own risk tolerance before making investment decisions.